| Business Summary | | Anika
Therapeutics,
Inc.
develops,
manufactures
and
commercializes
therapeutic
products
and
devices
intended
to
promote
the
repair,
protection
and
healing
of
bone,
cartilage
and
soft
tissue.
Orthovisc
is
a
hyaluronic
acid
(HA)
product
used
in
the
treatment
of
some
forms
of
osteoarthritis
in
humans,
and
is
currently
approved
for
sale
and
marketed
in
Canada,
Europe,
Turkey
and
Israel.
Hyvisc
is
a
HA
product
used
in
the
treatment
of
equine
osteoarthritis.
Amvisc
and
Amvisc
Plus
are
HA
products
used
as
viscoelastic
supplements
in
ophthalmic
surgery
for
Bausch
&
Lomb
Surgical.
The
Company
is
currently
developing
Incert,
which
is
a
family
of
HA-based
products
designed
for
use
in
the
prevention
of
post-surgical
adhesions.
In
collaboration
with
Orquest,
Inc.,
Anika
also
has
exclusive
rights
to
produce
Ossigel,
an
injectable
formulation
of
basic
fibroblast
growth
factor
combined
with
HA
and
designed
to
accelerate
the
healing
of
bone
fractures. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Anika
Therapeutics,
Inc.
develops,
manufactures
and
commercializes
therapeutic
products
based
on
hyaluronic
acid
(HA)
used
to
promote
the
protection
and
healing
of
bone,
cartilage
and
soft
tissue.
For
the
six
months
ended
6/30/01,
revenues
fell
21%
to
$5.1
million.
Net
loss
totaled
$5
million,
up
from
$783
thousand.
Revenues
reflect
lower
unit
prices.
Higher
loss
also
reflects
the
underutilization
of
manufacturing
capacity
and
a
$951
thousand
litigation
settlement
charge. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY2000 Pay | |
| Douglas Potter, 50 CEO,
Chief Financial Officer | $196K | Charles Sherwood, Ph.D., 54 Pres,
COO | 208K | Michael Slater, 54 VP
of Operations | 199K | Edward Ross, Jr., 44 VP
of Sales and Marketing | 184K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|